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THE EFFICACY OF BETAHISTINE AS TREATMENT FOR EUSTACHIAN 
TUBE DYSFUNCTION IN AN ALLERGIC RAT MODEL 
JAMES DAVID WILSON 
ABSTRACT 
 Otitis media is a quite common disease, especially in children due largely 
to their underdeveloped Eustachian tubes. One potential factor, thought to be a 
large contributor to the disease, is an allergic reaction causing congestion and 
blockage of the Eustachian tube, leaving the middle ear prone to bacterial 
infection and effusions. The H3 receptor has recently been discovered in the 
nasal mucosa of humans and rodents and is linked to the immune response. 
Excess histamine released in an allergic response causes nasal vascular 
constriction and congestion. By blocking the H3 receptor, the local vasculature 
may be allowed to dilate, resulting in decongestion. This could play a large role in 
the treatment of otitis media with effusion. 
 The effectiveness of betahistine dihydrochloride, an H3 receptor blocker, in 
providing possible relief from middle ear congestion was tested using a rat 
model. An allergic response was induced in rats followed by one of two 
betahistine dihydrochloride treatment regimens: drug delivery via transtympanic 
or intranasal route. Changes in Eustachian tube function were monitored during 
this process. Four measurements were used to measure the function of the 
Eustachian tube: passive opening pressure, passive closing pressure, active 
clearance of negative pressure, and Mucociliary transit time. Lower opening 
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pressure and closing pressure, higher clearance of negative pressure, and 
shorter Mucociliary transit time were indications of better Eustachian tube 
function. 
 Regardless of delivery method, no significant results were found among 
the experimental groups to suggest improved Eustachian tube function after drug 
treatment. Although the middle dose of betahistine dihydrochloride (50 mg/mL) 
delivered transtympanically followed the expected response outcome, the trend 
did not achieve statistical significance. Overall, the results of this study are 
inconclusive for measuring the beneficial effects of betahistine dihydrochloride on 
Eustachian tube function. Further investigations are being conducted to measure 
the magnitude and duration of the effects of allergic responses on Eustachian 
tube anatomy and physiology. 
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INTRODUCTION 
1. Otitis Media 
 Otitis media encompasses a variety of disease states that fall across a 
spectrum from acute to chronic and as symptomatic or asymptomatic (Stool, 
1998). Otitis media is a large concern for public health as $4 billion is spent 
annually for its evaluation and treatment (Durland et al., 2000).  It is divided into 
two main forms that have differing symptoms and effects: acute otitis media 
(AOM) and otitis media with effusion (OME), the latter being of greater relevance 
to this study. Half of all children will have at least one occurrence of AOM in their 
first year of life and greater than 60% of children are affected by age 2 
(Casselbrant & Mandel, 2003), while the incidence of OME is impossible to 
determine due to its general lack of symptoms. 
 AOM is diagnosed clinically based on three components: 1) visible 
infection of middle ear, 2) moderate to severe bulging of the middle ear, and 3) 
redness of the manubrium and tympanic membrane (TM) (Siddiq, Grainger, & 
Prentice, 2014). These factors typically are accompanied by a rapid onset of 
discomfort in the affected ear suggestive of a viral infection (AAPS, 2004). Other 
factors that could also indicate the presence of AOM include milder bulging of TM 
and tugging/holding of the ear. When a patient does present with AOM, 
antibiotics are the primary modality of treatment. A risk-benefit analysis should be 
determined before beginning an antibiotic regimen. With the use of antibiotics 
come certain risks, including nausea and allergic reaction which must be taken 
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into account along with the possibility that a “watch and see” observational 
approach may allow AOM to run its course without requiring therapeutic 
intervention. If AOM does not resolve upon initial observation or application of 
topical decongestant to the nasopharynx through the nose, delayed treatment 
does not have a significant effect on the efficacy of therapeutic treatments 
(AAPS, 2004). Figure 1 below shows the standard of care for a patient following 
the initial decision to treat with antibiotic or observation.  
 
Figure 1. Standard of care for treatment of patient following initial decision of 
antibiotic treatment versus observation (AAPS, 2004). 
 
 OME can occur as a sequela to AOM, or without history of prior infection, 
and differs from AOM in its clinical presentation. Also known as “glue ear,” OME 
is characterized by a buildup of fluid in the middle ear cavity behind the tympanic 
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membrane (TM) that is unable to be cleared through the Eustachian tube (Gates 
et al., 2002; van Zon et al., 2012). Though commonly lacking symptoms, OME is 
a concern nonetheless. When OME of unknown duration is found upon exam, 
spontaneous resolution is much less common than when the onset of disease is 
known (Casselbrant & Mandel, 2003). By allowing a buildup of fluid in the middle 
ear, there is a short-term conductive hearing loss. If the effusions persist, 
especially in the case of bilateral OME, more significant hearing loss can occur 
accompanied with impaired development of speech and normal behavior 
(Shekelle et al., 2002; Gouma et al., 2011). 
 Furthermore, it is important for providers to better distinguish between 
AOM and OME in the future. Deferring antibiotic use in OME may allow the 
process to resolve on its own and could lead to 8 million fewer antibiotic 
prescriptions annually (Dowell et al., 1998). Bacterial resistance is currently of 
great concern when it comes to the use of antibiotics in the community as well as 
the individual. With antimicrobial use there is an increased likelihood of resistant 
bacteria settling in the body that will not respond to subsequent therapy (Dowell 
et al., 1998)  
 
2. Eustachian Tube 
 The Eustachian tube (ET), which provides information between the middle 
ear and nasopharynx, is an important component of normal middle ear function. 
Some of its important functional roles include regulation of middle ear air 
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pressure, transportation of secretions away from the middle ear by ciliary 
movement, and a barrier to entry of sound pressure and fluids present in the 
nasopharynx (Takahashi et al., 1989; Fireman, 1997). These functions are 
illustrated below in Figure 2. Anatomically there are several differences between 
child and adult ET that can help explain the increased incidence of OME in the 
young. These differences include the diameter, angle, and musculature of the ET 
(Holborow, 1970, 1975). With a smaller diameter, more horizontal orientation, 
and lower frequency of opening due to immature tubal muscles, the young ET is 
physiologically less suitable for clearance of foreign material from the middle ear 
(Mann et al., 1979). If an obstruction occurs in the ET, which for the 
aforementioned reasons is much more likely in a child, negative middle ear 
pressures can occur as the trapped air of the middle ear is taken up by 
surrounding mucosa. As this negative pressure is created by the absorbance of 
air, effusions from the tissues of the middle ear often present themselves as a 
consequence (J. M. Bernstein, 1996). 
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Figure 2. Functions of Eustachian Tube in Regulation of Middle Ear. A) 
Allows equalization of middle ear pressure with atmosphere. B) Allows drainage 
of fluids from middle ear to nasopharynx with aid of ciliary action. C) Protects 
middle ear from sound pressure and nasopharyngeal secretions (Fireman, 1997). 
 
 
3. Pathogenesis of OME 
 Historically the prevalence of OME in young children has been attributed 
to an immature ET as discussed previously, which leads to improper drainage of 
the middle ear. Though this is one factor, allergy has been found to be another 
important factor. In fact, children with allergic rhinitis (AR) are twice as likely to 
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develop OME as children with no reported allergies (Draper, 1967).  The middle 
ear is a common locus for allergy and effusion causing agents, resulting in the 
swelling and obstruction of the ET that can lead to OME (Bernstein, 1975; 
Labadie et al., 1999; Sobol et al., 2002).  The allergic response can be 
generalized as follows: an antigen presenting cell, such as a dendritic cell, 
carries a particular allergen (i.e. pollen, pet dander, dust mite fecal protein, etc.) 
to a CD4+ T-lymphocyte which in turn releases a variety of interleukins and other 
TH2 cytokines into the blood stream (Oates et al., 1991). These cytokines then 
interact with plasma cells, mast cells, and eosinophils, which ultimately produce 
the immunoglobulins that respond to repeated exposures of the allergens.  This 
process is known as sensitization and is visualized below in Figure 3. 
Furthermore, the responses to repeated allergen exposures can be divided into 
an early phase response (EPR) followed by a late phase response (LPR).  
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Figure 3. Sensitization to Allergen. An allergen is presented to a CD4+ T cell 
by the antigen-presenting cell (dendritic cell) where it is processed and ultimately 
allergen-specific IgE antibodies are created to respond to subsequent exposure 
to the same allergen (Oates et al., 1991). 
 
A. Early Phase Response 
 The EPR occurs shortly after repeat exposure to an allergen and leads to 
symptoms including itching, sneezing, and runny nose (Skoner, 2001). This rapid 
response is mediated by the presence of immunoglobulin E (IgE) coated mast 
cells being present in the surface epithelium of the exposed area. Once there is 
an interaction between IgE and allergen, the mast cells degranulate causing the 
symptoms related to EPR (Oates et al., 1991).  Degranulation products causing 
EPR include histamine, kininogenase, and heparin. Other products released by 
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the mast cells, but not stored in the granules, include prostaglandin D2 and a 
variety of leukotrienes that cause swelling and leaking of blood vessels, which 
results in the fluid present in a runny nose. Local glands are also stimulated 
during this process to release mucoglycoconjugates and antimicrobial materials 
that cause sinus filling via local blood vessel dilation as well as afferent nerve 
stimulation, resulting in the sensation of itching and action of sneezing (Mygind & 
Naclerio, 1993). A schematic for the EPR along with the LPR can be seen below 
in figure 4. 
 
B. Late Phase Response 
 Clinically, the LPR is similar to that of the EPR with added congestion, 
fatigue, irritability, and even a potential decrease of cognitive function (Pollock et 
al., 2002).  LPR is characterized by goblet cell hyperplasia causing an increase in 
mucous production and secretion, recruitment of inflammatory cells including 
eosinophils, and tissue swelling. These effects have been shown to last 1-2 days 
following allergen exposure and leave the tissue in a highly sensitive state for 
repeat activation of the EPR for several subsequent weeks (Fadal, 1993). A 
previous study in our lab has supported the presence of LPR for at least 36 hours 
following exposure of allergen to the middle ear confirmed by the presence of 
Eustachian tube dysfunction and middle ear effusions (Hardy et al., 2001).  
During the time period leading up to the LPR, chemoattractant cytokines, 
including some of the interleukins, cause protective granular cells to accumulate 
	  9 
around the area of allergen exposure (Naclerio et al., 1985). These protective 
cells, once activated, promote reactivation of the EPR pathway as well as leading 
to longer-lasting changes in the makeup of nasal tissue. The more a subject is 
exposed to an allergen the less of the allergen is needed to evoke the allergic 
response.  This phenomenon is known as “priming” and is of interest because it 
can leave the body more prone to respond to other allergens (Connell, 1969). 
Figure 4 below gives a visual representation of how the body responds to 
allergens following sensitization. 
 
Figure 4. Early and Late Phase Response to Repeated Allergen Exposure. 
Once the body has been sensitized to a particular allergen, repeated exposure to 
that allergen sets in motion the simplified pathway above.  The EPR is illustrated 
to the left and LPR occurs as the diagram progresses to the right (Oates et al., 
1991).  
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4. Histamine  
 Mast cells (and other granular cells) release histamine during an allergic 
response, which has been shown to be responsible for eliciting symptoms of AR. 
It is a neuromodulatory compound capable of causing sneezing, overactive 
glandular release, and vasodilation leading to congestion along with its other 
functions throughout the body (Monroe et al., 1997). Several investigations have 
shown that symptoms of AR can be evoked in non-allergic subjects simply by 
giving them an application of histamine, thus demonstrating its important role in 
the allergic process (Doyle et al., 1990; Rajakulasingam et al., 1993; Howarth et 
al., 2000).  
 Histamine causes its effects on the nasal mucosa largely through its 
interaction with the to the H1 receptor (Hilberg et al., 1995). H2 receptor mediated 
effects of histamine may contribute to the mucosal response, but the evidence of 
its role in the process is not nearly as strong as that of the H1 receptors (Wood-
Baker et al., 1996). H1 receptor blockers are commonly used for treatment of AR 
alleviating sneezing and hypersecretion but have not been effective in relieving 
blockage (Nakaya et al., 2005).  
 A third histamine receptor, H3 has been found to have a role as a 
presynaptic autoreceptor, essentially monitoring the level of histamine released 
by histaminergic neurons (Arrang et al., 1983). Originally thought to only be 
present in the central nervous system, the H3 receptor has recently been shown 
to be present in the nasal mucosa of both humans and rodents (Nakaya et al., 
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2005; Suzuki et al., 2008) and has a complicated pharmacology consisting of 
around 20 isoforms (Hancock et al., 2003). Furthermore, these receptors have 
been demonstrated in association with both sympathetic nerve endings and 
submucosal glands, suggesting a role in the allergic pathway (Taylor-Clark at al., 
2005; Suzuki et al., 2008). By blocking H3 receptors, histaminergic neurons 
continue to release histamine as well as acetylcholine, norepinephrine, serotonin 
and other neurotransmitters (West et al., 1990).  It has been suggested that 
activation of the sympathetic pathway via this inhibition of the H3 receptor could 
serve a role in decongestion by causing vasoconstriction of local vasculature 
(Taylor-Clark et al., 2005). Despite this further release of histamine, the 
sympathetic effects appear to have a greater impact on ET function (Franz et al., 
2011). A fourth recently discovered histamine receptor (Nguyen et al., 2001), H4, 
is located in the nasopharynx along with H3 receptors, but as yet little is known 
about its function or if it has a role in the nasal allergic response (Nakaya et al., 
2005). Table 1 summarizes the location, function, and nasal symptoms produced 
by the four known histamine receptors. 
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Table 1. Histamine Receptors and Their Functions (Taken from Lieberman, 2011). 
 
Abbreviations: AV, atrioventricular; CNS, central nervous system; GI, gastrointestinal; 
NK, natural killer. 
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5. Betahistine as Therapeutic 
 The compound betahistine is known for its antagonistic effects on the H3 
receptor, while also showing mild agonistic effects on the H1 receptor (Arrang et 
al., 1985), though more recently it has been reclassified as an inverse agonist to 
the H3 receptor (Hancock, 2006). Betahistine has been in clinical use for quite 
some time primarily to treat balance disorders, including Meniere’s disease 
(Rascol et al., 1995). The more recent finding of H3 receptors located in the nasal 
mucosa has opened the possibility for additional therapeutic use of the drug, 
including treatment of AR and OME.  
 As mentioned previously, H1 receptor blockers typically are able to 
alleviate the symptoms of sneezing and hypersecretion in AR, but not blockage. 
Recent evidence has shown support for the use of betahistine in improving ET 
function in non-allergic Sprague-Dawley rats with the use of a topical intranasal 
application suggesting that the beneficial effects are primarily due to H3 receptor 
specificity, rather than H1 (Franz et al., 2011). Further support for the H3 receptor 
hypothesis comes from the observation that ciproxifan, a pure H3 receptor 
antagonist, shows similar beneficial effects on ET function and that intranasal 
drug delivery is preferable to systemic administration (Franz et al., 2011). 
 Hydrostatic properties such as surface tension and adhesion can affect 
the pressure needed to open the ET (Hills, 2002). Therefore changes in ET 
function are likely due, in part, to changes in the makeup and amount of 
secretions in the ET lumen (Franz & Anderson, 2007). Currently, it is thought that 
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the nasopharyngeal side of the ET controls tubal opening via musculature and 
secretary cell presence. Franz (2011) investigated the question of whether or not 
intranasal application of betahistine had strong enough local effects on the 
nasopharyngeal side of the ET to alter adhesive forces holding the tube closed, 
finding that intranasal topical application had the same effect as when the drug 
was applied transtympanically into the middle ear cavity and forced through the 
ET with use of positive pressure (Franz et al., 2011). 
 
6. Specific Aims/Objectives 
 The objective of the study is the test whether betahistine can improve ET 
function in an allergic rat model in hope of providing a viable clinical alternative to 
use of antibiotics in OME patients. Specifically, the study will attempt to answer 
the following questions: 
1) Does the use of betahistine improve ET function in an allergic rat 
model? 
2) Is one of the drug delivery methods, transtympanic or intranasal, more 
effective than the other? 
3)  What dosage of betahistine is most efficacious as treatment? 
 Bacterial resistance as a result of antibiotic usage is a large concern to the 
world population. By finding an alternative to antibiotic treatment for a common 
disease process like OME that leads to an abundance of yearly antibiotic 
prescriptions (especially in children), it is hoped the progression of bacterial 
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resistance can be hampered. Treatment of middle ear inflammation should 
always be closely monitored due to the potential lasting effects of persistent 
effusion presence. 
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METHODS 
1. Laboratory Animals 
 All animals were handled in compliance to an Institutional Animal Care 
and Use Committee (IACUC) approved protocol (University of North Carolina at 
Chapel Hill). Brown Norway rats between 150-300 grams were used as the 
experimental subjects. Initially the rats were divided into two groups representing 
two unique drug delivery methods: a transtympanic approach (TT) and an 
intranasal approach (IN). These delivery classes were then further subdivided 
into five or six treatment groups for the transtympanic and intranasal class, 
respectively, as shown in Table 2 below. Each delivery approach had a 
phosphate buffered saline (PBS) control group and an allergic control group. 
Rats were randomly assigned to their treatment groups.  
Table 2. Drug delivery methods and treatment groups. 
Group Transtympanic Approach  (TT) Intranasal Approach (IN) 
I PBS Control PBS Control 
II Allergic Control Allergic Control 
III 10 mg/mL Treatment 10 mg/mL Treatment 
IV 50 mg/mL Treatment 50 mg/mL Treatment 
V 200 mg/mL Treatment 100 mg/mL Treatment 
VI --- 200 mg/mL Treatment 
 
 The TT group was studied prior to the IN group and followed a timeline 
displayed below in Figure 5. Small modifications to the timeline were made 
before continuing with the IN groups including adding an extra treatment dose 
and removing the final challenge day (see Figure 6). These changes were 
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applied as a result of the findings from the TT group and will be further discussed 
below. 
 
Figure 5. Timeline for Transtympanic Group. For these animals, ovalbumin 
(OVA), challenges were delivered transtympanically as were betahistine 
dihydrochloride treatments. Treatment box: 10 mg/ml = TT Group III; 50 mg/ml = 
=TT Group IV; 200 mg/ml = TT Group V. SQ, subcutaneous injection.  
 
 
 
 
	  18 
 
Figure 6. Timeline for Intranasal Group. For these animals, ovalbumin (OVA) 
challenges and betahistine dihydrochloride treatments were delivered via an 
intranasal delivery method. Treatment box: 10 mg/ml = IN Group III; 50 mg/ml = 
IN Group IV; 100 mg/mi = IN Group V; 200 mg/ml = IN Group VI. SQ, 
subcutaneous injection. 
 
 
  
2. Sensitization and Challenges 
 PBS Control Group. Rats in the Phosphate buffered saline (PBS) 
sensitized control group (Group I, Table 2) received sterile PBS solution, pH 7.4 
(1 X PBS-Cell Culture Grade; Lineberger Tissue Culture Facility, Chapel Hill, NC) 
on all sensitization and challenge days indicated in Figures 5 and 6. Challenges 
administered through the tympanic membrane consisted of 35 microliters of PBS 
delivered via syringe directly to the middle ear. Intranasal challenges consisted of 
!
!
!
!
!
!
!
!
!
!
! !
!
!
Day!
0! 7! 21! 26!27! 29! 33! 37! 41! 43!!
Sensitization!
1.2!mg!OVA!SQ!
Intranasal!Challenge!
0.1!mg!OVA!
Treatment!
10!mg/ml!dose!
50!mg/ml!dose!
100!mg/ml!dose!
200!mg/ml!dose!
Eustachian!Tube!evaluation!
Eustachian!Tube!evaluation!
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50 microliters of PBS sprayed directly into the nasopharynx via the right nostril by 
a Paasch airbrush (Paasch Airbrush VL231135, Chicago, IL).  
 Allergic control and treatment groups. Rats in the ovalbumin (OVA) control 
group (Group II, Table 2) and all treatment group (Group II - VI, Table 2) were 
sensitized to OVA (A5503; Ovalbumin, Sigma-Aldrich Co., St. Louis, MO) via 
subcutaneous injections of 1.2 mg OVA in 0.6 mL PBS and 5.14 mg aluminum 
hydroxide (21645-51-2; Aluminum Hydroxide Gel Dried USP, EMD Chemicals 
Inc., Gibbstown, NJ) in 0.6 mL PBS as a local adjuvant on days 0 and 7. Rats in 
the TT delivery class received 0.1 mg of OVA in 35 microliters of PBS 
transtympanically on challenge days and those in the IN delivery class received 
0.1 mg of OVA in 50 microliters of PBS via an intranasal route.  
 
3. Treatment 
 A formulation of betahistine dihydrochloride was supplied by Otifex 
Therapeutics Pty Ltd (Melbourne, Australia) as a stock solution with 
concentration of 200 mg/mL. This formulation was used as treatment for the 
subjects following sensitizations and challenges at the original concentration (200 
mg/mL) or diluted to 10 mg/mL, 50 mg/mL, or 100 mg/mL. All dilutions were 
made with the same clinical grade vehicle (proprietary) in which the drug is 
carried.  
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4. Assessment of Eustachian Tube Function 
 The procedures used in this experiment are adapted from those described 
previously (Hardy et al., 2001; Ebert et al., 2002, 2006). To begin, the subjects 
were anesthetized with a mixture containing 91 mg/mL of ketamine and 9 mg/mL 
of xylazine. After being weighed, the animals were anesthetized and then placed 
in a lateral recumbent position on a thermistor controlled heating pad. The 
heating pad was used to keep the subject’s body temperature at a constant level 
throughout each evaluation. The TM of the subject was then visualized though an 
operating microscope. Once visualized, a myringotomy was performed with a 27-
gauge needle in the anterior-inferior portion of the tympanic membrane to serve 
as a connection between the middle ear and infusion/withdrawal pump system 
(BS-8000 Multi-Phaser Programmable Syringe Pump, Braintree Scientific Inc., 
Braintree, MA). See Figure 7 for a summary diagram of the experimental 
procedures and apparatus.  
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Figure 7. Pressure Measurement Apparatus Setup.  After a myringotomy is 
performed to create a hole in the TM (4), the rubber cuff (3) of the Foley catheter 
when inflated creates a closed system between the middle ear (5), 
infusion/withdrawal pump (2), and water monometer (1). As pressure is added or 
removed from the system, the water level of the monometer changes to serve as 
a gauge that measures the pressure level of the system in cm H2O (Ebert et al., 
2006). 
 
 Using a technique originally described by Flisberg et al. (1963), the 
passive opening and closing pressures of the ET were made able to be 
quantified as follows. Firstly, a 6 French latex pediatric Foley catheter with a 3 
mL balloon (6 French latex; Medline; Mundelein, IL) was inserted in the ear canal 
of the subject and the balloon was inflated to create an airtight seal following a 
myringotomy. The opposite end of the Foley catheter was attached to a T-
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connector and coupled to a water monometer with pressure measurements 
labeled in cm H2O and a Braintree infusion pump to either introduce or remove 
pressure from the system at a uniform rate of 16 mL/min. 
 As pressure was slowly introduced into the system, the water monometer 
reflected the growing pressure in the system. Once the pressure built to a level at 
which the Eustachian tube was forced open, the meniscus of water in the 
monometer reversed from convex to concave representing the passive opening 
pressure (POP). At this point, the infusion/withdrawal pump was turned off and 
pressure was released through the Eustachian tube. Once the monometer 
settled at a certain value, it was determined that the Eustachian tube was closed 
and the value was recorded as the passive closing pressure (PCP). 
 In order to quantify the ability of the Eustachian tube to actively clear 
middle ear pressure, subjects were put in a supine position. A nasal speculum 
was used to visualize the back of the mouth. The infusion/withdrawal pump was 
then used to create a negative pressure of -10 cm H2O in the middle ear. Once 
this negative pressure system was created, the rat hypopharynx was stimulated 
with a piece of 0.047” outer diameter silicone tubing attached to the end of 
polyethylene tubing to induce repeated swallowing. The tubing caused the tensor 
veli palatini muscle to contract, which in turn caused a temporary active opening 
of the Eustachian tube. Thus, each time the rat swallowed, a small amount of 
pressure was able to escape from the system and be visualized as the water 
monometer level gradually returned back toward 0 with subsequent swallows. 
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Once the monometer level stabilized, and the animal was stimulated to induce 10 
additional swallows with no further pressure release, it was deemed the rat had 
cleared the negative pressure to its greatest possible extent. The difference in 
pressures between the start point and end point of swallow stimulation was 
divided by 10 cm H2O to obtain a percentage active clearance of negative 
pressure (ACNP).  A diagram of the three pressure measurements across time 
can be seen below in Figure 8.
 
Figure 8. Distinguishing the Pressure Measurements. At point a, pressure is 
introduced to the system by the infusion/withdrawal pump until it reaches the 
POP. This pressure, point b, occurs when the Eustachian tube opens and the 
shape of the meniscus in the water monometer changes from concave to convex. 
When the POP is reached, the infusion/withdrawal pump is turned off and 
pressure is allowed to exit the system through the Eustachian tube. Once 
pressure is no longer exiting the system indicating the Eustachian tube is closed, 
the PCP has been reached (point c). The infusion/withdrawal pump is then used 
again to withdrawal pressure to -10 cm H2O and swallows are induced until 
pressure no longer exits the system indicating the ACNP. POP- Passive Opening 
Pressure, PCP- Passive Closing Pressure, ACNP- Active Clearance of Negative 
Pressure. 
ACNP
60
0
-10
POP
PCP
a.
b.
c.
d.
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 During the final evaluation of Eustachian tube function, a measure of 
ciliary function was included called the mucociliary transit time (MCTT). To 
measure the MCTT it was necessary for the subject to be deeply anesthetized 
due to the invasive nature of the procedure needed to split the soft palate. The 
subject was placed again in the supine position and the soft palate visualized 
with the aid of a nasal speculum and operating microscope. A midline incision 
was then made just posterior to the hard palate transecting the entire soft palate. 
Hemostasis was maintained with small balls of cotton being held with pressure 
by forceps. Once the soft palate had been opened, a miniature hand mirror could 
be positioned within the incision and used to visualize the opening of the 
Eustachian tube into the nasopharynx. The subject was then moved to the lateral 
recumbent position and the tympanic membrane was once again visualized. A 
syringe with a 27-gauge needle filled with blue dye (Coomassie Brilliant Blue, B-
0149; Sigma Chemical Co., St. Louis, MO) was then used to inject a few drops 
into the bulla transtympanically. Once injected, a timer was used and the animal 
was returned to the supine position in order to visualize the opening of the ET 
into the nasopharynx.  
 Once blue dye was visualized escaping through the ET, the timer was 
stopped, indicating the MCTT. The maximum time waited for visualization of the 
blue dye was 15 minutes, as our preliminary observations suggested that if the 
dye had not escaped within 15 minutes, it never would. Once a MCTT was 
recorded, 1 mL of potassium chloride was injected via an intracardiac route as 
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euthanasia. Once euthanized, the subjects were decapitated as a second 
method of sacrifice.  
 
5. Changes to the Transtympanic Versus Intranasal Timeline 
 Modifications were made to the experimental timeline prior to continuing 
with the IN group of which three can be noted in Figures 5 and 6 above. First, the 
final challenge following treatment was eliminated. By eliminating the final 
challenge, the overall timeline shortened from 44 to 43 days. Also, the affected 
ear/Eustachian tube was switched from left to right in the IN group due to 
handedness of the experimenter.  
 
6. Statistical Analysis 
 All statistical analyses for this study were performed with the use of IBM 
SPSS Statistics 22. For the POP the Wilcoxon signed-rank test was used. This 
non-parametric test was used due to the fact that during several evaluations the 
Eustachian tube did not open, so an arbitrary value of 130 cm H2O representing 
the highest point of the monometer was used. For the PCP and ACNP a mixed 
ANOVA was used. The ACNP was made into a percentage of clearance prior to 
analysis. Finally for the MCTT, a one-was ANOVA was used. Graphs were 
created using the mean values of the measurements with standard error of 
measurement included. 
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RESULTS 
1. Transtympanic Approach 
A. Passive Opening Pressure 
The POP for the five transtympanic approach subgroups can be seen 
below in Figure 9. Values displayed are an average of the pressures experienced 
by the subjects of each experimental group. Blue columns represent measured 
values after sensitization and repeated challenges. Yellow columns represent 
values attained following treatment. No changes were found to be significant (p > 
0.05 using Wilcoxon signed-rank test). Starting from the left in the figure is Group 
I which experienced a rise in POP from 62.0 (+/- 4.0) to 74.5 (+/- 5.9). Group II 
experienced a rise in POP from 79.0 (+/- 11.4) to 83.6 (+/- 7.9) following 
treatment and final challenge. Groups III, IV, and V are arranged by increasing 
treatment dose. Group III experienced a rise from 64.6 (+/- 8.9) to 83.4 (+/- 8.8) 
after treatment. Group IV had the largest decrease in POP following treatment 
from 83.4 (+/- 10.8) to 63.8 (+/- 3.5). Though the average drop was large, it was 
not statistically significant likely due to large variation within the group. Lastly, 
group V had a minimal drop from 89.0 (+/- 10.7) to 87.6 (+/- 9.6). Despite the lack 
of significance for this measure, the 50 mg/mL (Group IV) treatment dose 
administered transtympanically did, by Day 44, reduce the opening pressure to 
near those of the PBS controls. 
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Figure 9. The Passive Opening Pressures (POP) of the Transtympanic 
Approach Groups. The POP of the Eustachian tube refers to the pressure at 
which the Eustachian tube opens during infusion of pressure into the middle ear. 
The measurements are organized by experimental subgroup including the two 
evaluation points for the subgroups. The blue bars refer to the measurement 
taken on day 29 following sensitization and challenges, and the yellow bars refer 
to a final measurement taken on day 44 following treatment dates and a final TT 
challenge. 
 
 
 
B. Passive Closing Pressure 
The passive closing pressure from the transtympanic approach group can 
be seen below in Figure 10. The values displayed are the average pressure 
values of the different experimental groups at the two evaluation dates. All PCP 
changes were non-significant (p> 0.05 using mixed ANOVA). Starting from the 
left on the x-axis, Group I experienced a rise in PCP from 42.8 (+/- 6.0) to 
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46.3(+/- 4.6). Group II PCP rose from 34.1 (+/- 1.4) to 41.5(+/- 3.9). Group III 
PCP average rose from 32.7 (+/- 2.9) to 41.8(+/- 3.4) while Group IV value fell 
from 39.1 (+/- 5.9) to 37.2(+/- 1.8). Lastly, Group V rose from 35.6 (+/- 8.0) to 
40.6(+/- 3.1). 
 
 
Figure 10. The Passive Closing Pressures (PCP) of the Transtympanic 
Approach Groups. The PCP of the Eustachian tube refers to the pressure at 
which the Eustachian tube closes, visualized by cessation of monometer level 
change following opening. The measurements are organized by experimental 
subgroup including the two evaluation points for the subgroups. The blue bars 
refer to the measurement taken on day 29 following sensitization and challenges 
and the yellow bars refer to the second measurement taken on day 44 following 
treatment dates and a final TT challenge.  
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C. Active Clearance of Negative Pressure 
The percentage of negative pressure reduced by active clearance can be 
seen below in Figure 11. No recorded changes in ACNP were found to be 
significant (p>0.05 using mixed ANOVA). Starting from the left on the figure, 
Group I demonstrated less clearance at the final post-treatment evaluation with 
the percentage of clearance dropping from 28.8 (+/- 6.9) to 25.9 (+/- 9.8). Group 
II experienced an increase in clearance from 27.9 (+/- 7.6) to 30.5 (+/- 11.8). 
Group III percentage dropped from 19.3 (+/- 8.7) to 9.3 (+/- 4.1) following 
treatment. Group IV rose in clearance from 18.9 (+/- 9.5) to 31.6 (+/- 12.0). 
Group V displayed a drop in clearance following treatment from 17.8 (+/- 5.9) to 
12.8 (+/- 5.5). Of the three treatment groups only Group IV (50 mg/mL) had a 
large increase in clearance following treatment. 
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Figure 11. The Active Clearance of Negative Pressure (ACNP) of the 
Transtympanic Approach Groups. The ACNP refers to the percentage of -
10cm H2O released by stimulated swallowing during light anesthesia with 100% 
being the maximum. The measurements are organized by experimental 
subgroup including the two evaluation points for the subgroups. The blue bars 
refer to the measurement taken on day 29 following sensitization and challenges 
and the yellow bars refer to a final measurement taken on day 44 following 
treatment dates and a final TT challenge.  
 
 
 
D. Mucociliary Transit Time 
For this measure, two types of outliers were removed from MCTT 
analysis. One type was animals where the dye never appeared after 15 minutes, 
and the other was where the dye appeared in less than 30 seconds (dye 
presented itself by means determined not to be due to ciliary action). The 
resultant means with outliers removed can be seen below in Figure 12. No 
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statistically significant differences were found between the TT approach groups, 
F (4,28)=1.783, P=0.160. From left to right, Group I had a value of 204.5 seconds 
(+/- 78.4). Group II had an average clearance time of 92.4 seconds (+/- 28.0). 
The low treatment group, Group III, had the fastest clearance of 61.0 seconds 
(+/- 10.5). Group IV cleared the blue dye at an average of 125.7 seconds (+/- 
21.1). Group V had an average clearance of 114.8 seconds (+/- 36.1).  
 
Figure 12. The Mucociliary Transit Time (MCTT) of the Transtympanic 
Approach Groups. The MCTT refers to the amount of time for blue dye injected 
transtympanically to travel from the middle ear to the opening of the ET in the 
nasopharynx via ciliary action. The MCTT measurement was taken on the final, 
post-treatment evaluation (day 44). The means of the five subgroups are 
displayed with standard error bars included.  
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2. Intranasal Approach 
A. Passive Opening Pressure 
The POP for the six intranasal approach subgroups can be seen below in 
Figure 13. Blue columns represent measured values after sensitization and 
repeated challenges. Yellow columns represent values attained following 
treatment. No challenge following treatment was performed in the IN approach 
group. Starting from the left of the figure is Group I, which experienced a 
statistically significant (p=0.028) drop in POP from 72.9 (+/- 3.2) to 64.1 (+/- 3.1). 
Group II experienced a fall in POP from 71.5 (+/- 3.3) to 67.5 (+/- 2.1) following 
treatment. Next, the four treatment groups, Groups III-VI, are arranged by 
increasing dose of treatment. The low dosage group, Group III, experienced a 
drop from 65.2 (+/- 1.2) to 61.9 (+/- 2.7) after treatment. Group IV experienced a 
slight fall in POP following treatment from 63.9 (+/- 5.0) to 63.0 (+/- 3.0). Group V 
fell from 69.4 (+/- 3.0) to 64.7 (+/- 2.9). Lastly, Group VI rose slightly from 65.2 
(+/- 3.1) to 66.3 (+/- 3.3). 
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Figure 13. The Passive Opening Pressures (POP) of the Intranasal 
Approach Groups. The POP of the Eustachian tube refers to the pressure at 
which the Eustachian tube opens during infusion of pressure into the middle ear. 
The measurements are organized by experimental subgroup including the two 
evaluation points for the subgroups. The blue bars refer to the measurement 
taken on day 29 following sensitization and challenges, and the yellow bars refer 
to a final measurement taken on day 44 following treatment dates and a final TT 
challenge. Star denotes statistical significance. 
 
 
 
B. Passive Closing Pressure 
 The PCP averages for the IN approach group can be found below in 
Figure 14. All subgroups experienced a rise in PCP following treatment. Group I 
demonstrated a rise of 32.7 (+/- 2.2) to 35.0 (+/- 1.0). Group II rose from 33.5 (+/- 
2.8) to 37.2 (+/- 2.3). Group III showed a rise from 27.8 (+/- 1.2) to 34.2 (+/- 2.4). 
Group IV rose significantly (p=0.005) from 28.3 (+/- 2.7) to 33.1 (+/- 2.6). Group V 
72.9	   71.5	   65.2	   63.9	   69.4	   65.2	  64.1	   67.5	   61.9	   63.0	   64.7	   66.3	  
0.0	  
10.0	  
20.0	  
30.0	  
40.0	  
50.0	  
60.0	  
70.0	  
80.0	  
PBS	  Control	  
Group	  (I)	  
Allergic	  Control	  
Group	  (II)	  
10	  mg/mL	  Tx	  
Group	  (III)	  
50	  mg/mL	  Tx	  
Group	  (IV)	  
100	  mg/mL	  Tx	  
Group	  (V)	  
200	  mg/mL	  Tx	  
Group	  (VI)	  
Pr
es
su
re
	  (c
m
	  H
2O
)	  
Intranasal	  POP	  
Post-­‐SensiMzaMon/Challenges	   Post-­‐Treatment	  
	  34 
rose from 27.7 (+/- 1.9) to 33.5 (+/- 2.6), and in Group VI average PCP rose from 
29.9 (+/- 2.2) to 35.0 (+/- 1.6) following treatment. 
 
Figure 14. The Passive Closing Pressures (PCP) of the Intranasal Approach 
Groups. The PCP of the Eustachian tube refers to the pressure at which the 
Eustachian tube closes, visualized by cessation of monometer level change 
following opening. The measurements are organized by experimental subgroup 
including the two evaluation points for the subgroups. The blue bars refer to the 
measurement taken on day 29 following sensitization and challenges and the 
yellow bars refer to the second measurement taken on day 44 following 
treatment dates and a final TT challenge. Star, statistical significance. 
 
 
 
C. Active Clearance of Negative Pressure 
The percentage ACNP for the IN group is shown below in Figure 15. 
Group I demonstrated a significant drop (p=0.046) following treatment from 42.6 
(+/- 6.0) to 31.7 (+/- 3.4). Group II experienced an increase in clearance from 
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30.3 (+/- 8.5) to 38.0 (+/- 11.1). Of the four treatment groups, both Group III and 
Group V showed an increase in clearance following treatment. Group III average 
percentage rose from 50.9 (+/- 7.2) to 62.6 (+/- 9.1) following treatment. Group IV 
dropped in clearance from 64.0 (+/- 15.1) to 50.0 (+/- 15.5). Group V displayed 
an increase in clearance following treatment from 38.0 (+/- 9.3) to 59.5 (+/- 11.3). 
Finally, the high dosage treatment group, group VI, had a drop in ACNP from 
31.0 (+/- 12.8) to 28.7 (+/- 6.5). 
 
Figure 15. The Active Clearance of Negative Pressure (ACNP) of the 
Intranasal Approach Groups. The ACNP refers to the percentage of -10cm 
H2O released by stimulated swallowing during light anesthesia with 100% being 
the maximum. The measurements are organized by experimental subgroup 
including the two evaluation points for the subgroups. The blue bars refer to the 
measurement taken on day 29 following sensitization and challenges and the 
yellow bars refer to a final measurement taken on day 44 following treatment 
dates and a final TT challenge. Star, statistical significance. 
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D. Mucociliary Transit Time 
The IN subgroups showed no significant differences between evaluations 
in terms of their MCTT, F (5,26)= 0.370, p=0.160. Group I experienced an 
average MCTT of 206.7 seconds (+/- 34.9). Group II had a quicker average 
MCTT at 122.5 seconds (+/- 22.4). The lowest treatment group, Group III, had an 
average MCTT of 216.0 seconds (+/- 101.4). Group IV average was 194.0 (+/- 
61.7). Next, Group V MCTT average was 153.8 (+/- 46.2). The largest dosage 
treatment group, Group VI, had the highest average MCTT at 247.5 (+/- 122.3) 
 
Figure 16. The Mucociliary Transit Time (MCTT) of the Transtympanic 
Approach Groups. The MCTT refers to the amount of time for blue dye injected 
transtympanically to travel from the middle ear to the opening of the ET in the 
nasopharynx via ciliary action. The MCTT measurement was taken on the final, 
post-treatment evaluation (day 43). The means of the six subgroups are 
displayed with standard error bars included.  
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DISCUSSION 
 Systemically sensitizing the rats to OVA and delivering challenges of the 
allergen to the Eustachian tube via the middle ear or the nasopharynx was 
expected to produce an inflammatory allergic response affecting functions of the 
Eustachian tube. One function of the ET is to carry debris away from the middle 
ear. Cilia line the Eustachian tube connecting the middle ear to the nasopharynx 
and have a natural tendency to carry foreign material away from the middle ear 
toward the nasopharynx (Sade, 1966). The expectations were for the 
sensitization and challenge with ovalbumin to decrease the effectiveness of this 
important function and betahistine would improve the ET function in a dose-
dependent manner. Improved ET function is characterized by lower POP, PCP, 
and MCTT and higher ACNP in our study. However, the negative pressure 
clearance from the middle ear has been shown in previous studies to be the most 
reliable measure of ET function (Miller, 1965; Takahashi et al., 1989; Hardy et al., 
2001; White et al., 2002).  
 
1. Effects of Drug Treatment 
 No convincing, significant changes in ET function were found between 
pre- and post-treatment measures regardless of delivery method or dose level. 
However, the 50 mg/mL treatment group (Group IV, TT) showed a trend in the 
predicted direction in regards to POP and ACNP suggesting possible 
improvement in ET function following treatment at this dose. Because ET 
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function does not improve with the 10 mg/mL dose (Group III, TT) it is proposed 
the agent is not pharmacologically effective at this concentration. The 200 mg/mL 
dose (Group V, TT) did not show any signs of improvement in ET function 
perhaps due to increased effect on the H1 receptor. For the most part, the 
intranasal results were not very telling, though there were a few significant data 
measures. The PBS control group (Group I, IN) showed ET function improved 
with regard to POP. There is evidence suggesting saline alone can improve 
congestion via intranasal application, which supports the POP results (Tomooka 
et al., 2000). However, the ACNP for Group I, IN suggests the contrary with 
Group IV, IN showing a significant result as well in regards to PCP. Because the 
sample sizes were small in this study (10 per group, TT; 6-7 per group, IN), tests 
for normality were not possible giving less credibility to the p-value. 
 
2. Limitations in Method and Effects on Future Investigations 
 Multiple TM puncture. The possibility of ET function being affected by 
repeated TM puncture during myringotomy is a concern based on the suggested 
impairment of function in the PBS control group of with TT delivery. By 
performing fewer myringotomies in the IN delivery subjects, it was hoped the 
potential for myringotomy-induced dysfunction of the ET would be limited. 
 Masking. After completion of the TT delivery timeline, it was decided to 
adjust the IN timetable based on the premise that during the final challenge in the 
TT group, some or all beneficial drug effects might have been reversed by 
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repeated OVA challenge. Unfortunately, the IN data did not show much variability 
among the groups, nor have we yet tested this for the TT delivery route. 
 Allergen exposure. By changing the challenge schedule between TT and 
IN delivery regimens, the ET received less exposure to the allergen under the IN 
conditions. In nature, repeated exposure to allergens is common due to the 
subject’s environment, therefore it could be that a single spray of allergen via an 
intranasal path simply is not sufficient to evoke a substantial allergic response, or 
it could be activating the EPR but not the LPR necessary for longer lasting 
effects of allergic response. Previous studies showed the direct application of 
histamine to the nasal mucosa was sufficient to elicit LPR, but it could be the 
case that an isolated exposure to allergen is not enough to initiate the LPR (Ebert 
et al., 2002). This factor is especially important when considering the MCTT. Cilia 
line the entirety of the ET into the middle ear and by only delivering the allergen 
into the nasopharynx, it is unlikely many cilia will be affected. Therefore the IN 
MCTT should remain within the subject-to-subject natural variability. For further 
studies, it would likely be more beneficial to make the delivery of allergic 
challenge consistent with TT delivery, only altering the delivery of the drug. 
 Time. Another issue affecting the results could be the time elapsed prior to 
the post-challenge evaluation. By waiting two days with no further exposure of 
allergen, the end of the LPR is approached which could be leading to the natural 
return of normal ET function. In future evaluations, it would be reasonable to 
evaluate ET function one day following the final challenge.  
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 Drug Combinations. Recently, use of antibiotic therapy has been shown to 
lead to quicker clearance of fluid in the middle ear in combination with systemic 
steroids than antibiotic therapy alone (Simpson et al., 2011). Similar studies with 
H3 receptor blockers, rather than antibiotics, should be conducted to test the 
viability of further steroid use as synergistic therapy. Alternative delivery methods 
should also be considered. Current research shows the feasibility of a non-
invasive transtympanic delivery of drug using magnetized nanoparticles, allowing 
a more sustained and targeted delivery to the affected ET (Sarwar, 2013). 
 
3. Final Remarks 
 While the results presented are not entirely persuasive there is evidence 
that the 50 mg/mL dose may be beneficial when considering Group IV, TT. Given 
the shortcomings in the methods discussed above and the small size of our 
samples it seems that continued investigation with betahistine is warranted, 
especially in light of information from the National Ambulatory Medical Care 
survey. This survey showed that rates of otitis media visits in the ER significantly 
dropped from 1995-1996 to 2005-2006, but the proportion of visits that result in 
antibiotic prescriptions has remained constant around 80% of cases in the same 
time period suggesting alternative treatment options for otitis media should be 
further assessed (Grijalva et al., 2009).  
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